Top

Published in:

Open Access 01-12-2008 | Research article

Spectrum and characterisation of BRCA1 and BRCA2deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer

Authors: Eva Machackova, Lenka Foretova, Mirka Lukesova, Petra Vasickova, Marie Navratilova, Ilse Coene, Hana Pavlu, Veronika Kosinova, Jitka Kuklova, Kathleen Claes

Published in: BMC Cancer | Issue 1/2008

Abstract

Background

The incidence of breast cancer has doubled over the past 20 years in the Czech Republic. Hereditary factors may be a cause of young onset, bilateral breast or ovarian cancer, and familial accumulation of the disease. BRCA1 and BRCA2 mutations account for an important fraction of hereditary breast and ovarian cancer cases. One thousand and ten unrelated high-risk probands with breast and/or ovarian cancer were analysed for the presence of a BRCA1 or BRCA2 gene mutation at the Masaryk Memorial Cancer Institute (Czech Republic) during 1999–2006.

Methods

The complete coding sequences and splice sites of both genes were screened, and the presence of large intragenic rearrangements in BRCA1 was verified. Putative splice-site variants were analysed at the cDNA level for their potential to alter mRNA splicing.

Results

In 294 unrelated families (29.1% of the 1,010 probands) pathogenic mutations were identified, with 44 different BRCA1 mutations and 41 different BRCA2 mutations being detected in 204 and 90 unrelated families, respectively. In total, three BRCA1 founder mutations (c.5266dupC; c.3700_3704del5; p.Cys61Gly) and two BRCA2 founder mutations (c.7913_7917del5; c.8537_8538del2) represent 52% of all detected mutations in Czech high-risk probands. Nine putative splice-site variants were evaluated at the cDNA level. Three splice-site variants in BRCA1 (c.302-3C>G; c.4185G>A and c.4675+1G>A) and six splice-site variants in BRCA2 (c.475G>A; c.476-2>G; c.7007G>A; c.8755-1G>A; c.9117+2T>A and c.9118-2A>G) were demonstrated to result in aberrant transcripts and are considered as deleterious mutations.

Conclusion

This study represents an evaluation of deleterious genetic variants in the BRCA1 and 2 genes in the Czech population. The classification of several splice-site variants as true pathogenic mutations may prove useful for genetic counselling of families with high risk of breast and ovarian cancer.

Available only for authorised users

Foretova L, Petrakova K, Palacova M, Kalabova R, Navratilova M, Lukesova M, Vasickova P, Machackova E, Kleibl Z, Pohlreich P: Genetic and preventive services for hereditary breast and ovarian cancer in the Czech Republic. Hereditary Cancer in Clinical Practice. 2006, 4: 3-6.CrossRefPubMedPubMedCentral

Lux MP, Fasching PA, Beckmann MW: Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med. 2006, 84: 16-28. 10.1007/s00109-005-0696-7.CrossRefPubMed

Ford D, Easton DF, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998, 62: 676-689. 10.1086/301749.CrossRefPubMedPubMedCentral

Easton DF, Ford D, Bishop DT, Breast Cancer Linkage Consortium: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995, 56 (1): 265-271.PubMedPubMedCentral

Antoniou A, Pharoah PD, Narod S, Rish HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallopniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003, 72: 1117-1130. 10.1086/375033.CrossRefPubMedPubMedCentral

Narod SA: Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer. 2002, 2: 113-123. 10.1038/nrc726.CrossRefPubMed

Friedman LS, Ostermeyer EA, Szabo CI, Down P, Lynch ED, Rowel SE, King MC: Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet. 1994, 8: 399-404. 10.1038/ng1294-399.CrossRefPubMed

Mazoyer S, Dunning AM, Serova O, Dearden J, Puget A, Healey CS, Gayther SA, Mangion J, Stratton MR, Lynch HT, Goldgar DE, Ponder BAJ, Lenoir GM: A polymorphic stop codon in BRCA2. Nat Genet. 1996, 14: 253-254. 10.1038/ng1196-253.CrossRefPubMed

Spain BH, Larson CJ, Shihabuddin LS, Gage FH, Verma IM: Truncated BRCA2 is cytoplasmic: Implications for cancer-linked mutations. Proc Natl Acad Sci USA. 1999, 96: 13920-13925. 10.1073/pnas.96.24.13920.CrossRefPubMedPubMedCentral

10.

Hoffman JD, Hallam SE, Venne VL, Lyon E, Ward K: Implications of a novel cryptic splice site in the BRCA1 gene. Am J Med Genet. 1998, 80: 140-144. 10.1002/(SICI)1096-8628(19981102)80:2<140::AID-AJMG10>3.0.CO;2-L.CrossRefPubMed

11.

Claes K, Poppe B, Machackova E, Coene I, Foretova L, De Paepe A, Messiaen L: Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2. Genes Chromosomes Cancer. 2003, 37: 314-320. 10.1002/gcc.10221.CrossRefPubMed

12.

Judkins T, Hendricson BC, Deffenbaugh AM, Scholl T: Single nucleotide polymorphisms in clinical genetic testing: The characterization of the clinical significance of genetic variants and their application in clinical research for BRCA1. Mutation Research. 2005, 573: 168-179.CrossRefPubMed

13.

Claes K, Machackova E, De Vos M, Mortier G, De Paepe A, Messiaen L: Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 Flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. Hum Mutat. 1999, 13: 256-10.1002/(SICI)1098-1004(1999)13:3<256::AID-HUMU12>3.0.CO;2-M.CrossRefPubMed

14.

Vasickova P, Machackova E, Lukesova M, Damborsky J, Horky O, Pavlu H, Kuklova J, Kosinova V, Navratilova M, Foretova L: High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic. BMC Med Genet. 2007, 8: 32-10.1186/1471-2350-8-32.CrossRefPubMedPubMedCentral

15.

O'Donovan MR, Freemantle MR, Hull G, Bell DA, Arlett CF, Cole J: Extended-term cultures of human T-lymphocytes: a practical alternative to primary human lymphocytes for use in genotoxicity testing. Mutagenesis. 1995, 10: 189-201. 10.1093/mutage/10.3.189.CrossRefPubMed

16.

Antonarakis SE, the Nomenclature Working Group: Recommendations for a nomenclature system for human gene mutations. Hum Mutat. 1998, 11: 1-3. 10.1002/(SICI)1098-1004(1998)11:1<1::AID-HUMU1>3.0.CO;2-O.CrossRefPubMed

17.

Meindl A, German Consortium for Hereditary Breast and Ovarian Cancer: Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer. 2002, 97: 472-480. 10.1002/ijc.1626.CrossRefPubMed

18.

Claes K, Poppe B, Coene I, Paepe AD, Messiaen L: BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. Br J Cancer. 2004, 90: 1244-51. 10.1038/sj.bjc.6601656.CrossRefPubMedPubMedCentral

19.

Brzovic PS, Meza JE, King MC, Klevit RE: BRCA1 RING domain cancer-predisposing mutations. Structural consequences and effects on protein-protein interactions. J Biol Chem. 2001, 276: 41399-41406. 10.1074/jbc.M106551200.CrossRefPubMed

20.

Ruffner H, Joazeiro CAP, Hemmati D, Hunter T, Verma IM: Cancer-predisposing mutations within the RING domain of BRCA1: Loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. PNAS. 2001, 98: 5134-5139. 10.1073/pnas.081068398.CrossRefPubMedPubMedCentral

21.

Breast Cancer Information Core Database. [http://research.nhgri.nih.gov/bic/]

22.

Gorski B, Byrski T, Huzarski T, Lakubowska A, Menkiszak J, Gronwald J, Pluzanska A, Babenek M, Fisher-Maliszewska L, Grzybowska E, Narod SA, Lubinski J: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian Cancer. Am J Hum Genet. 2000, 66: 1963-1968. 10.1086/302922.CrossRefPubMedPubMedCentral

23.

Reese MG, Eeckman FH, Kulp D, Haussler D: Improved splice site detection in Genie. J Comput Biol. 1997, 4: 311-323.CrossRefPubMed

24.

Fang LJ, Simard MJ, Vidaud D, Assouline B, Lemieux B, Vidaud M, Chabot B, Thirion JP: A novel mutation in the neurofibromatosis type 1 (NF1) gene promotes skipping of two exons by preventing exon definition. J Mol Biol. 2001, 307: 1261-70. 10.1006/jmbi.2001.4561.CrossRefPubMed

25.

Thomassen M, Kruse TA, Jensen PK, Gerdes AM: A missense mutation in exon 13 in BRCA2, c.7235G>A, results in skipping of exon 13. Genet Test. 2006, 10: 116-120. 10.1089/gte.2006.10.116.CrossRefPubMed

26.

Bieche I, Lidereau R: Somatic genetics of breast cancer. Bull Cancer. 1997, 84: 83-96.PubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/8/140/prepub

Title: Spectrum and characterisation of BRCA1 and BRCA2deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer
Authors: Eva Machackova
Lenka Foretova
Mirka Lukesova
Petra Vasickova
Marie Navratilova
Ilse Coene
Hana Pavlu
Veronika Kosinova
Jitka Kuklova
Kathleen Claes
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-8-140

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2008

Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres

DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection

Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families

Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines

Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer

Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance

Keynote webinar | Spotlight on antibody–drug conjugates in cancer